Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) on Wednesday acquired privately held iRenix Medical Inc., adding late-stage investigational ocular antiseptic IRX-101 to its ophthalmology pipeline.
• Tarsus Pharmaceuticals shares are sliding. Why is TARS stock dropping?
The transaction includes approximately $75 million in upfront consideration and up to $490 million in potential regulatory and commercial milestone payments.
William Blair said the acquisition represents an opportunistic pipeline expansion through a disciplined deal structure that relies primarily on future milestones.
The upfront payment consists of $37.5 million in cash and $37.5 million in Tarsus common stock.
Additional payments are contingent on future approval and commercialization milestones, bringing the potential transaction value to as much as $565 million.
IRX-101 Demonstrated Improvements In Late-Stage Trial
IRX-101 is a stable aqueous chlorine dioxide solution being developed as an ocular antiseptic for patients undergoing intravitreal therapy.
The investigational treatment is designed to reduce post-procedural pain and corneal toxicity compared with povidone-iodine (Betadine), the current standard antiseptic.
The completed Phase 2b/3 RELIEF trial enrolled 154 patients and met both co-primary endpoints. Compared with povidone-iodine, IRX-101 produced an approximately 50% relative reduction in post-procedural pain scores, with half of the treated patients reporting a pain score of zero.
The study also showed an approximately 25% relative reduction in corneal fluorescein staining, a measure of corneal surface damage, indicating less injury to the cornea following the procedure.
Phase 3 Study Planned for 2027
Based on the Phase 2b/3 findings and feedback from the U.S. Food and Drug Administration, Tarsus plans to launch a Phase 3 study evaluating the tolerability and safety of IRX-101 against povidone-iodine.
The company expects patient enrollment to begin in the first half of 2027, with trial results anticipated in 2028.
William Blair said the acquisition gives Tarsus access to a late-stage clinical asset through what it described as a disciplined transaction structure, with most of the financial commitment tied to future clinical and commercial milestones rather than upfront payments.
Analyst Lachlan Hanbury-Brown wrote, “Given the company’s track record of identifying unmet needs in eye care and successful development and commercialization, we see the expansion into retina as a promising evolution as management leverages the foundation it has built with Xdemvy.”
“We view this transaction as a positive, as it potentially expands future revenue streams with a late-stage product entering a large TAM with unmet need and little competition, while also improving the patient experience and offering financial incentives to physicians,” Hanbury-Brown further added.
TARS Stock Price Activity: Tarsus Pharmaceuticals shares were down 7.84% at $62.42 at the time of publication on Thursday, according to Benzinga Pro data.
Photo: Shutterstock